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Abstract Apheresis only partially controls raised low density 
lipoprotein cholesterol levels in patients with homozygous fa- 
milial hypercholesterolemia, who usually respond poorly to 
lipid-lowering drugs. The efficacy and mechanism of action 
of a new 3-hydroxy-3-methylglutaryl coenzyme A reductase in- 
hibitor, atorvastatin, was therefore investigated in seven ho- 
mozygotes undergoing apheresis. One receptor-negative and 
six receptor-defective homozygotes undergoing plasma ex- 
change or LDL apheresis every 2 weeks were studied during 
2 months each on placebo and on atorvastatin 80 mg daily. 
Changes in plasma lipids and mevalonic acid, an index of 
cholesterol synthesis, were measured and the kinetics of the 
rebound of low density lipoprotein cholesterol and apolipo- 
protein B after apheresis were analyzed. All subjects had sig- 
nificant improvements on atorvastatin. Mean decreases in low 
density lipoprotein cholesterol were 31% greater both pre- 
and post-apheresis on atorvastatin compared with placebo, ac- 
companied by a 63% decrease in mevalonic acid. Percentage 
changes in low density lipoprotein cholesterol and mevalonic 
acid were closely correlated ( r  = 0.89, P = 0.007). The mean 
production rates of low density lipoprotein cholesterol and 
apolipoprotein B were 21% and 25% lower, respectively, on 
atorvastatin than on placebo (P < 0.005 and <0.02) but 
changes in mean fractional clearance rates were not statisti- 
cally significant.l We conclude that atorvastatin enhances 
the efficacy of plasma exchange and low density lipoprotein 
apheresis in patients who lack low density lipoprotein recep- 
tors. This effect appears to be due to marked inhibition of 
cholesterol synthesis which results in a decreased rate of pro- 
duction of low density lipoprotein.-Marais, A. D., R. P. 
Naoumova, J. C. Firth, C. Penny, C. K. Y. Neuwirth, and 
G. R. Thompson. Decreased production of low density lipo- 
protein by atorvastatin after apheresis in homozygous familial 
hypercholesterolemia. J. Lzfid Res. 1997. 38: 2071-2078. 
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Familial hypercholesterolemia (FH) is characterized 
by a dominantly inherited increase in the level of low 
density lipoprotein (LDL) in plasma, and a marked pre- 
disposition for the premature onset of atherosclerotic 
vascular disease. FH is due to mutations affecting one 
or both alleles encoding the LDL receptor, more than 
150 of which have been described (1). Inheritance of 
two mutations gives rise to the clinical phenotype of ho- 
mozygous FH, although in the majority of instances 
such individuals are genetically compound heterozy- 
gotes rather than true homozygotes (2). If left un- 
treated, phenotypic homozygotes usually die in their 
second or third decade from severe atherosclerotic 
involvement of their coronary arteries, especially the os- 
tia, and aortic root. 
The highest frequency of FH occurs in South Africa 
where 1 in 100 white Afrikaners are affected, due to a 
founder gene effect in emigrants from Europe (3). The 
introduction of plasma exchange (4), and subsequently 
LDL apheresis (5),  has improved the prognosis of ho- 
mozygotes (6) but aortic stenosis remains a frequent 
and dangerous complication, often necessitating surgi- 
cal intervention (7). 
In an effort to reduce LDL levels still further, aphere- 
sis is frequently combined with treatment with a 3- 
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re- 
ductase inhibitor (statin). In homozygotes, lovastatin or 
simvastatin reduced LDL cholesterol by only an addi- 
tional 11.5-16% below the level obtained with apheresis 
alone (8,9). However, much greater reductions in LDL 
Abbreviations: LDL, low density lipoprotein; FH, familial hypercho- 
lesterolemia; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; 
apoB, apolipoprotein B; MVA, mevalonic acid; HDL, high density 
lipoprotein; FCR, fractional catabolic rate; VLDL, very low density 
lipoprotein. 
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are achievable in FH heteroqytcs ,  wliow I)c(ter rc- 
sponse to statins is attributable to t l i r i r  having ot i ly  ;I 
partial deficiency of' I,DL receptors, thc. c3xprcssion of' 
which is markedly enhanced in vivo by ph;iriiiacologic;11 
inhibition of endogenous cholesterol synthesis ( I O ) .  
Recently we reported the ability of atoivastatin, ;I new 
HMG-CoA reductase inhibitor, to decreasc cholesterol 
synthesis and lower LDI, cholesterol in hrterozyg-o-olis 
FH (1 1).  Here we describe the efficac), oL' aton'astiitiii 
a s  an adjunct to plasma exchange o r  LDL. apheresis in 
the treatment of' homozygous FH, including a receptoi'- 
negative subject, and provide evidence that the reduc- 
tion in LDL is achieved mainly via a dccreased rate of 
production. 
SUBJECTS AND METHODS 
Seven post-pubertal patients with phenotypically ho- 
mozygous FH were studied, five in South Africa and two 
in Britain. Their clinical features and the nature of the 
associated LDL receptor gene mutations have been de- 
scribed previously (9, 12, 13). Patients were designated 
as receptor negative or receptor defective, depending 
upon whether LDL binding by their cultured fibroblasts 
or Epstein-Barr virus transformed lymphoblasts was < 
or > 2% of normal (14). 
All patients had been undergoing apheresis at 2-week 
intervals for several years and continued to do  so during 
the study. The South African patients were treated with 
plasma exchange (9), the British patients underwent 
LDL apheresis, using disposable dextran sulphate/ccl- 
Idose columns (15). The study design was an open label 
comparison of placebo and atorvastatin, 80 mg daily, 
each for a period of 8 weeks during which apheresis was 
maintained as usual. Exclusion criteria were previous 
portacaval shunt, serum triglyceride >4.5 mmol/L., he- 
patic dysfunction, and taking of drugs influencing lipid 
metabolism or known to interact with HMG-CoA reduc- 
tase inhibitors. 
Serum transaminase and creatinine phosphokinase 
measurements were performed every 2 weeks, prior to 
apheresis. Blood samples for serum lipid and lipopro- 
tein assays were taken between 8-9 AM after an over- 
night fast immediately before and after apheresis 011 
three consecutive occasions during the second half of' 
each treatment period; mean values were iisecl f o r  statis- 
tical analysis. The rebound of LDL, was studied in each 
patient for 14 days after apheresis first on placebo and 
then on atorvastatin, each on three occasions in Cape 
Town and once in London. Total and high density lipo- 
protein (HDL) cholesterol, triglycerides, and apolipo- 
protein (apo)B were assayed by standard niethods in the 
local lal)oracor? and LI)L c.holcstcro1 \ZXS c.,iIciil;icc.cI 
( 1  6). 1'1;istn;i ine\xlonic. ;icitl .  2111 indcx  of i I ~ o l ~ ~ ~ t ~ ~ i ~ o I  
synthesis, \ t x s  mialyzccl i t i  fi-orcn s;unplcs i t i  l . o t i ( I o t ~ .  
21s previously described (1 1) .  Fasting lrwls a t i t l  dittixiiil 
changes in plasma mevalonic acid ("A) i n  Iiuniaiis 
have been showii to correlate witti the rcsdts ol'sc.\cr;il 
other methods of estimating cholesterol syntliesis, in- 
cluding sterol balancr (1 ?)+ dcutt.riitm tiptiikt' inro 
ttcwly synthesized cholesterol (18), and assay ol'liepatic 
HMG-CoA reductase acti\ity (19). 1 1 1  addition, wc rc- 
cctitly showed a good cot-relation betwc.cn climgcs i t 1  
plasma MVA and lathosterol, a later precui-sor ol'choles- 
terol, in FH subjects undergoing I.DL aphcrc 
Plasma voltiiiie in liters w;~s calculated as 4..3% o t  I)otly 
mass in kilogrmis. 
The production and fractional clearaiicc rates of'LDI 
cholesterol and apoB during the 2-week intenA be- 
t~vcen consccritive apheresis wcrc calculated froin the 
equatioii: 
LDL cholesterol (mmol/L) o i  
apoB (mg/dl) at time t (days) = 
Although independently derived, this equation can bc 
rearranged to that published by Apsteill et al. (2 1 ) for 
use in the non-steady state (see Appendix) and assumes 
that LDL mass (m) is contained in a single intravascular 
compartment that has a post-apheresis mass (Inl,), ii  
zeru order production rate (u) ,  and a first order clear- 
ance rate (k) and that these parameters do not vary dut-- 
ing the 2 weeks rebound period. The parameters 11 and 
k were calculated by non-linear regression using Prism 
(Graphpad Software). The validity of the equation was 
tested by calculating LDL apoB production rates in two 
homozygotes (not in this study) in  whom non-steady 
state turnover of "?' I-labeled LDL had been determined 
in the past (22). By summing the absolute catabolic rate 
of LDL apoB and the daily increment in plasma I D L  
apoB after apheresis, production rates in the two sub- 
jects undergoing non-steady state isotopic tiitmover 
studies were estimated as 26.8 and 23.3 ing/kg per day 
versus 31.5 and 19.4 mg/kg per day by kinetic analysis 
of the post-apheresis rebound of' LDL-apoR using n o n -  
linear regression. 
Data are presented as means 2 standard error 01. the 
mean (SEM) . Statistical significance of differences dut-- 
ing treatment was evaluated by paired t-test and by one- 
way analysis of' variance for repeated measrircrnents 
(XNOVA) fc)r normally distributed data. The Mann- 
Whitiiey test was tiset1 to  compare data with it skewed 
distribution, i.e., seruin triglycerides. The relationship 
between t l i e  changes iii LDL, cholesterol and pI:isn~;i 
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TABLE 1.  Clinical characteristics of seven homozygous FH patients 
Plasma Lipids" 
N o ,  0 1  Study Sex TC TC H D I X  1.DI.A; L.DI,-Rrccpu)r Mutation 
mmol/l  
Age at Time 
1 1 :3 M 15.1 1.2 0.60 
2 13 F 28.7 1.7 0.65 
3 19 F 18.1 0.9 0.50 
4 19 M 18.1 2.0 0.60 
6 26 M 23.5 1 .0 0.80 
7 52 M 15.4 1 .3 
Mean _f SE 20.8 i 2.6 19.8 -+ 1.8 1.22 t 0.2 0.65 i 0.05 
5 24 F 19.5 0.4 o.ao 
- 
13.9 
27.3 Pro664L.eu and null" 
17.2 Asp154Asn' and Unknown'' 
16.6 .bp'LOGGlu' and Unknown" 
18.5 A%p206Glu' and Asp206Glud 
22.2 Glu387Lys and Glu387Lysd 
- Asp206Glu/ and Val408Mett" 
Exon 7/8 de lehn"  and exon 7/8 deletion' 
19.2 +- 1.9 
"Values were recorded before commencing apheresis. 




'Atrikaner I .  
CAfrikaner 2. 
MVA was examined by linear regression analysis. A 
value of P < 0.05 was considered significant. 
These studies were approved by the Research Ethics 
Committees of the University of Cape Town and the 
Hammersmith Hospitals Trust. All patients gave in- 
formed consent and continue to receive atorvastatin on 
a compassionate use basis. 
RESULTS 
The ages at time of the study and pre-treatment se- 
rum lipids of the four male and three female patients 
are shown in Table 1. Three were true homozygotes, 
one of whom was receptor-negative. The other two and 
the remaining four compound heterozygotes were re- 
ceptor-defective. 
Changes in serum lipids and lipoproteins 
Mean LDL cholesterol levels on placebo and on ator- 
vastatin are shown in Fig. 1. Pre- and post-apheresis val- 
ues were both 31% lower while on atorvastatin (8.17 t 
0.30 and 2.04 5 0.11 versus 11.90 rt 0.42 and 2.97 f 
0.33 mmol/L, P = 0.0004 and 0.026). 
Decreases in LDL cholesterol on atorvastatin com- 
pared with placebo (Table 2) were mirrored by de- 
creases in total cholesterol (9.21 ? 0.33 vs. 13.08 t 0.51 
mmol/L or -29%, P = 0.0004). Decreases in apoB 
(183 2 10 vs. 238 t 20 mg/dl or 23%, P =  0.001) were 
less marked (Table 3). Corresponding changes in se- 
rum triglyceride were 0.58 2 0.05 vs. 0.77 t 0.06 
mmol/L ( -23%,  P = 0.04). HDL cholesterol values 
were similar on atorvastatin and placebo (0.89 t 0.14 
vs. 0.81 -+ 0.07 mmol/L, respectively). 
Kinetic analysis of LDL cholesterol and apoB 
The mean post-apheresis rebounds in LDL choles- 
terol are shown during the placebo and treatment 
phase for the group in Fig. 2. The best fit values for 
production and clearance in each individual are indi- 
cated in Table 2. Analysis of these results showed that 
the slower rate of rebound of LDL cholesterol on ator- 
vastatin was due more to decreased production than to 
increased clearance. This trend was especially marked 
in the only receptor negative homozygote (Patient l),  
in whom production rate decreased by 21% but the 
computed fractional catabolic rate (FCR) did not 
change. Patient 2 behaved anomalously in that she 
showed not only a greater decrease in production rate 
than other patients on atorvastatin but also a marked 
decrease in FCR. The reasons are unclear but it is note- 
12 . 
10 . ** 
LDL-C 8 
mmoVl . 
4 -  
2 '  
0 -  
Pre-apheresis Post-apheresis 
Fig. 1, Plasma LDI, cholesterol (C) in Seven FH homozygotes under- 
going apheresis. Values represent the mean of three consecutive esti- 
mations at biweekly intervals during the second month on placebo 
(m) and atorvastatin 80 mg daily (0). **P = 0.0004 placebo vs. ator- 
vastatin (pre-apheresis); * P  = 0.026 placebo VS. atorvastatin (post- 
apheresis). 
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TAB1.E 2. l )ei- i \ed pi-oductioir r i i i d  clt.;iIcuicc rates of I . l ~ ! , - c h ~ r l c ~ ~ ~ ~ ~ r l  i i i  Iionio/.)gom 1.3 I p.r t i ( . i i \<  
iindei-going t)i-\veci+ ap1ici-c.iis while on plxcl~o mid on t i t o i y c i h t a t i i i  
l'soilu( iioii Ka~c 
_ _ _ _ _ ~ _ ~  -~ -~ ._~ .  ~~~ ~~. ~~- ~~.~ ..__. ~- ~-~ - ~ .  ~ - . ~ ~ .  ~~~- . -~ . ~~. -~ -~ .~ 
F n c  t io i i .11  (.lc:u .11iic l < , t ~ < ,  %'SI1111 1.1)1 ( ~ ~ l ( J ~ ( ' ~ l l ' l l ~ ~  
~- -.-.-. - -. -. - - ~-~..-~. __ -.__ ~~ - _ _ ~ ~  . ~ ~ -  ~ 
"I< cho ' . ion. ihtdt in  l ' l ~ i ~ c l ~ i l  
~ . _ ~ _ _ ~ _  - . ~  _-._.___ -..-. _ ~ _  -~ - 
/ IfJO/< / ( / ( I >  
I 2.52 I .w 0.126 0.126 10.7 8.7 
2 3.98 2.02 0.194 0.117 1 I .!$ 8.0 
9 j.52 4.23 0.116 0.131 I I .,I 8. I 
4 3.67 2.60 0.1 1 1 0.125 10.5 1 .1  
5 4.72 4.07 0.086 0.152 12.6 7.3 
6 3.91 0.009 0.1 .i(i 14.0 8.2 
7 6.5 1 0.141 0.161 12.1 0.7 
Mean .4.40 0.125 0 .  138' I I .YO 8.17 
SE 0.45 0.47 0.01 0.007 0.42 0.30 
- '  
___ - ~ _  _-. __ .- _ _ ~  -.-. ~ . ~ -  
"Pre-apheresis values. 
"/' = 0.0047, atorvastatin vh. placebo. 
'NS, atoivastatiti vs. placeho. 
worthy that she was one of the two youngest patients in 
the series and was undergoing a post-pubertal growth 
spurt (Table 1) .  
Analysis of the apoB rebound curves gave similar re- 
sults with a significant decrease in production rate on 
atorvastatin but no change in mean FCR (Table 3 ) .  Indi- 
vidual values of the latter decreased in two patients 
(nos. 2 and 4), increased in two (nos. 5 and 6),  and 
were virtually unchanged in the remainder. In contrast, 
production rates decreased to a greater or lesser extent 
in all seven patients. Mean decreases in LDL cholesterol 
and apoB production rates on atorvastatin were of simi- 
lar magnitude (21% and 25%, respectively). 
Changes in cholesterol synthesis DISCUSSION 
The acute ef'fects of apheresis on MVA levels were ex- 
amined in each patient, once while on placebo and 
once while on atorvastatin. As shown in Fig. 3, a signifi- 
cant rise in mean MVA levels was observed on the third 
day after apheresis while on placebo but not while on 
atorvastatin. 
Longer term effects of atorvastatin on cholesterol syn- 
thesis were examined by comparing mean pre-aphere- 
sis levels of plasma MVA during the second month of 
each treatment period. As shown in Fig. 4, mean values 
were 63% lower while on atorvastatin than on placebo. 
As shown in Figs. 5A and B, percentage decreases in 
plasma MVA correlated more closely with percentage 
change in LDL cholesterol ( r  = 0.89, P = 0.007) than 
with percentage change in apoB ( T  = 0.61, P = 0.06). 
Homozygous FH has hitherto been regarded as re- 
fractory to lipid-lowering drugs, necessitating the use of 
radical forms of therapy such as apheresis, portacaval 
'TABLE 3. Derived production and clearance rates of apolipoprotein B in homozygous FH patients 
undergoing biweekly apheresis while on placebo and on atorvastatin 
-___ 
Production Rate Fiarticrnal Clearance Rate S?rum apoB" 
__ 
N o .  l'lacrho ~\~OlVASl~lllll Plairho Atorvastatin Placebo t\tor\.astarin 
.____ - 
mg/&y ponls/d(ij  rn,q/(il 
1 624. I 526.1 0.196 197 I59 
2 1644.8 786.8 0.21 7 268 193 
9 17311.6 1320.8 0.299 0.2 14 200 I72 
4 944.2 538.3 0 .  I75 0.121 190 157 
5 1416.6 1094.ti 0.169 0.191 233 I70 
6 1247.6 12 13.6 0.1% 0.200 340 "8 
7 1821.5 1641.7 0.223 0.219 237 21.5 
Mean 1348.3 IO 1 7.4h 0.209 0.197' 237.9 183.4 





"P  = 0.019, atorvastatin VI. placcbo. 
'NS, atorvastatin vs. plareho. 
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6 -  
4 -  
2 -  
I Placebo 
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0.0 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 
days 
Fig. 2. Rate of rebound (mean 5 SE) of LDL cholesterol (C) after apheresis in seven homozygotes while on 
placebo or atorvastatin 80 mg daily. Goodness of fit (r') for placebo and atorvastatin rebounds were 0.91 and 
0.88, respectively. 
shunt, and liver transplantation. Although more haz- 
ardous, the latter procedure can sometimes result in 
normalization of serum lipids, by substituting a liver 
with a normal complement of LDL receptors for one 
that is deficient or defective in that respect (23). The 
greater severity of hypercholesterolemia in receptor- 
negative homozygotes and their reported lack of re- 
sponse to HMG-CoA reductase inhibitors (24) led to 
the concept that the raised LDL is largely attributable 
to hypocatabolism. However, there is also evidence of 
increased production of LDL via a very low density lipo- 
T 
Atorvastatin 
E I E 
Pre-apheresis 1 3 
Days 
Plasma mevalonic acid (MVA) immediately before and on Fig. 3. 
days 1 and 3 after apheresis in seven homozygotes while on placebo 
( P  < 0.05) and atorvastatin ( P  = 0.80). 
protein (VLDL) -independent pathway in homozygous 
FH ( 2 5 ) ,  presumably reflecting hepatic cholesterol 
overload secondary to increased influx of LDL via re- 
ceptor-independent pathways (26). Thus there are 
grounds for believing that not only hypocatabolism but 
also increased production of LDL contribute to ele- 
vated LDL levels in homozygotes. If so, this might ac- 
count for the LDL-lowering effect of portacaval 
shunting, which reduces both cholesterol synthesis and 
LDL secretion (27, 28), and also for the response to 
simvastatin seen in an FH homozygote with a mutation 
that precluded the formation of LDL receptors (29). 
10 . 
9 '  
8 '  
7 '  
6 '  
MVA 5 .  
ng/ml 
4 '  
3 '  
2 '  
0 '  
Placebo Atorvastatin 
Fig. 4. Effect of atorvastatin on plasma mevalonic acid (MVA) in 
seven FH homozygotes undergoing apheresis. Each value represents 
the mean of three consecutive estimations at  bi-weekly intervals dur- 
ing the second month on placebo (0) and on atorvastatin 80 mg daily 
(0). P = 0.001 placebo vs. atorvastatin. 
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Fig. 5. A: Correlation between percentage reductions i i i  LDI, rholes- 
terol and plasma MVA on atonmtatin ( r  = 0.89, /'= 0.007). €3: Coi-re- 
lation hetwecii percentdge reductions in I J L  apoB and plasma MVA 
011  atorvastatill (I' = 0.61, /' = 0.06). 
Atorvastatin is a synthetic and highly effective H M G  
CoA reductase inhibitor (30) which has recently been 
licensed in Britain and the USA. In FH heterozygotes, 
atorvastatin (80 mg daily) has been shown to lower 1,DL 
cholesterol arid plasma mevalonic acid levels by 54% 
and 5Y%, respectively ( 1 1 ) .  During the present study. 
reductions in LDL cholesterol additional to those 
achieved by either plasma exchange or LDL apheresis 
in homozygotes averaged 31 %. Measurement of plasma 
MVA levels during the 24 h after single, equal doses of 
atorvastatin and simvastatin in two homozygotes (31) 
and in 20 heterozygotes (32) showed that suppression 
of cholesterol synthesis was more prolonged after ator- 
vastatin. Animal studies indicate that atorvastatin is re- 
tained in the liver longer than lovastatin (33 )  and an 
analogous pharmacokinetic differential may exist in h r i -  
mans with respect to atowastatin and sinivastatin. 
The validity of our analysis of LDL kinetics is depen- 
dent upon certain assumptions, one of which is that all 
LDL is contained in a single intravascular coin part- 
ment. However, it has lorig been recognized that ap- 
proximately 25% of LDL apoB is located in an extravas- 
cular compartment which is in close equilibrium with 
the plasma pool (34). After apheresis, there is ; i t 1  inIIii?. 
of LDL from the extra\.ascular conipartrnrn I wliicli iip 
pears t o  reach equilibrium with the intravasciilai. 1.111 
pool within 4 days, based upon a study iii a l i o n i o ~ y g o t ~ ~  
in whom the distribution of ''I I-labeled 1,DL l x~ l i )~ -c '  and 
after apheresis was determined using a wholc' bod\ 
counter (unpublished data). Influx of' cxtr;ivasculat 
LDL during the first 4 days after apheresis might lead 
t o  overcstimation of production by the one-pool niodcl 
hut t o  a similar extent on placebo ; r n d  atoivastatin, a s  
pharmacological reduction of LDI, does not ;iIter i t 4  
iiitravascLilar/extra\'ascular distrihution (:35).  1 1 1  coil-  
trast, the assumption that the production rate rc'niaitis 
constant during the rebound period would p r~ i lx ih l~  
underestimate the initial production I'ates, h i t  oiice 
again both the placebo arid atonastatin phases would 
be affectcd to a similar extent in  relative terms. A s  state(1 
under Methods, iion-steady state analysis of' "'I-labelctl 
I,DL apoB turnover in two hoiriozygotes studied previ- 
ously gave values tor production rates that ivew i n  rc'ii- 
sonahlc :igrrement with those obtaincd in the sanic' sub- 
jects b y  the method u r d  in this s t u d y  (17.5%) l o w t * i -  and 
16.7% higher). With regard to  the estimation 01. F(X, 
analysis of  post-apheresis rebound ciirvcs i n  hypei-cho- 
lester-oleniic subjects has been shown to give values simi- 
lar to those obtained i n  steady-state studies, ;is wis tlis- 
cussed by Xpstein et al. (21). Despite its tlic'orctical 
limitations, the one-pool model originally described b y  
those authors, which M'C' have atlapted b y  the addition 
of' non-linear regression analysis, appears to provide es- 
timates of production rate and F(:R that aippi-oxirri;ite 
quite closely to those obtained b y  other methods. 
Based on the analysis of post-apheresis r.choiintl 
curvc's arid o n  the reduction of 1 ,DI. cholcstrrol and 
apoB in  ;I receptor-negative subject, otir data suggcst 
that the 1.DL-lowering rffect of atorvast;itiii i n  FH ho- 
mozygotes was exerted morc' via ;I tleci-rasc' i n  L D I ,  pro- 
duction than by an increase in 1.111, catabolism. Krtlric- 
tiom in I.DL cholesterol and plasma MYA cor-rt4;ltecl 
closely, implying that measures that tlecre 
t e i d  svrithesis lead to ;in accompanying decreasc in  thr 
prodiictiori of I,DL o r  its precrirsors. It has been pevi- 
ously shown that limitation o f  the cholesterol siipply b y  
inhibition of HM( ;-( :oA reductase rcducccl lipoprot cin 
secretion i n  the pcrfused rat liver mock1 (36) a i d  wc 
recently rcviewed work in cultiu-crl cells, aninial Iiiodc'ls, 
and humans which led 11s t o  conclude that thc. supply 01' 
cholesterol t o  the liver is a determinant of  lipopi-otc'iii 
secretion (?7);  the data from the present study AI-e in 
keeping with this hypothesis. 
Further support has come recc.ntly l'rom the olxetva- 
tion that aton..astatin exerts marked ti-iglyceride-low- 
ering properties (38)  which, i t  could be speculated, 
reflects rctluccd VI.DL, secretion. An alternative niechat- 
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nism, that atorvastatin promotes clearance of rem- 
nant particles by stimulating residual LDL receptor ac- 
tivity and thus reducing LDL production, would not 
explain its effects in the receptor-negative subject. Re- 
cently presented data in hypercholesterolemic mini- 
pigs showed that atorvastatin decreased LDL apoB pro- 
duction by reducing both the secretion of VLDL and 
its conversion to LDL but without influencing the FCR 
of either lipoprotein (39). However, it should be noted 
that in the present study five of the six receptor-defec- 
tive homozygotes exhibited an increase in the FCR of 
LDL cholesterol on atorvastatin, consistent with stimu- 
lation by the latter of whatever residual LDL receptors 
there were in the liver. 
Atorvastatin was well tolerated in these relatively 
short-term studies and no significant clinical or bio- 
chemical adverse events were observed. Assuming that 
the decreases in LDL cholesterol which occurred are 
maintained in the long-term, the combination of aphe- 
resis with atorvastatin would enable significantly better 
control of hypercholesterolemia in FH homozygotes 
than has been achievable hitherto other than by liver 
transplantation (40). If so, this should delay the onset 
of aortic stenosis, which has been shown to correlate 
with the product of age and cholesterol concentration 
throughout life (41), as well as help postpone death 
from coronary heart disease.@ii 
APPENDIX 
The equation for the rebound of lipoprotein was derived for a sim- 
ple compartmental model. This model assumes that the mass (m) of 
LDL cholesterol or apoB is contained in a single intravascular com- 
partment that has a post-apheresis mass (ml,), a zero order produc- 
tion rate (u),  and a first order clearance rate (k) and these parameters 
do not vary during the rebound. The equation describing the change 
in mass with time (dm/dt = LI - k .  m) was integrated for the bound- 
ary conditions where t = 0, m = m,, to yield mi,, = (u/k)  - [ (u /k )  
- ni,,]e-" or m,,) = (u/k) ( I  - e-L')  + m,,e-". 
Apstein et al. (21) made the same assumptions when they described 
the cholesterol concentration (C) at time t, in terms of a minimum 
(i.e., post-apheresis) cholesterol concentration (GhI) ,  the steady state 
cholesterol concentration before apheresis (C,,), and production rate 
(S) as well as a clearance constant (k ) .  Equation 3 thus became 
C / G 1  = (CJC,,)  - [ (CJC, , )  - 11e-l'. Noting that the steady state 
concentration of cholesterol gives the value for (S/ k ) ,  their equation 
can be shown to be identical with ours by substitution and re- 
arrangement. 
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